Jump to: navigation, search
Clinical data
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass321.158 g/mol
3D model (JSmol)

WikiDoc Resources for Lonidamine


Most recent articles on Lonidamine

Most cited articles on Lonidamine

Review articles on Lonidamine

Articles on Lonidamine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Lonidamine

Images of Lonidamine

Photos of Lonidamine

Podcasts & MP3s on Lonidamine

Videos on Lonidamine

Evidence Based Medicine

Cochrane Collaboration on Lonidamine

Bandolier on Lonidamine

TRIP on Lonidamine

Clinical Trials

Ongoing Trials on Lonidamine at Clinical Trials.gov

Trial results on Lonidamine

Clinical Trials on Lonidamine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lonidamine

NICE Guidance on Lonidamine


FDA on Lonidamine

CDC on Lonidamine


Books on Lonidamine


Lonidamine in the news

Be alerted to news on Lonidamine

News trends on Lonidamine


Blogs on Lonidamine


Definitions of Lonidamine

Patient Resources / Community

Patient resources on Lonidamine

Discussion groups on Lonidamine

Patient Handouts on Lonidamine

Directions to Hospitals Treating Lonidamine

Risk calculators and risk factors for Lonidamine

Healthcare Provider Resources

Symptoms of Lonidamine

Causes & Risk Factors for Lonidamine

Diagnostic studies for Lonidamine

Treatment of Lonidamine

Continuing Medical Education (CME)

CME Programs on Lonidamine


Lonidamine en Espanol

Lonidamine en Francais


Lonidamine in the Marketplace

Patents on Lonidamine

Experimental / Informatics

List of terms related to Lonidamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP.[1]

Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. This is due to its proven ability to inhibit energy metabolism in cancer cells, and to enhance the activity of anticancer agents.[1]

Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide. Results showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.[2]

A derivative of lonidamine, gamendazole, is in testing as a possible male contraceptive pill.[3]


  1. 1.0 1.1 Pelicano H, Martin DS, Xu RH, Huang P (August 2006). "Glycolysis inhibition for anticancer treatment" (PDF). Oncogene. 25 (34): 4633–4646. doi:10.1038/sj.onc.1209597. PMID 16892078.
  2. Prabhakara S, Kalia VK (August 2008). "Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine" (PDF). Indian J. Med. Res. 128 (2): 140–8. PMID 19001677.
  3. Tash, Joseph (July 2008). "A Novel Potent Indazole Carboxylic Acid Derivative Blocks Spermatogenesis and Is Contraceptive in Rats after a Single Oral Dose". Biology of Reproduction. 78 (6): 1127–1138. doi:10.1095/biolreprod.106.057810. PMID 18218612. |access-date= requires |url= (help)